Sinclair Unveils MaiLi® Extreme in China, Ushering in a New Era of Hyaluronic Acid Innovation

Hangzhou, China: Sinclair Pharma Limited (‘Sinclair’) proudly announces the launch of MaiLi ® Extreme (MaiLi E), the world’s first premium hyaluronic acid (HA) injectable product powered by U.S. patented OxiFree™ Technology1. The product was unveiled at the Sinclair Future Aesthetics Ceremony & MaiLi E launch event held at the Hangzhou Canal Culture Center.

Over 600 esteemed guests, including industry association leaders, academic experts, clinicians, and media, gathered to witness the debut of MaiLi E in China. The event also featured a groundbreaking performance by the renowned dancer and choreographer, Xie Xin, merging the worlds of dance and aesthetics in a visually stunning interpretation of Sinclair’s brand philosophy.

MaiLi E is manufactured using OxiFree™ Technology to achieve the crosslinking of hyaluronic acid within an anaerobic environment. This approach reduces the need for chemical crosslinker while preserving HA chain integrity. Overall, this slows HA degradation and delivers projection power and dynamic elasticity with lower product volume needed vs reference HA3. The result is a natural-looking, supple appearance which meets the growing consumer demand for understated elegance and long-term safety.

The approval of MaiLi E is based on a multi-center Chinese clinical trial2 led by Prof. Li Qingfeng of Shanghai Ninth People’s Hospital. This study involved 159 patients undergoing chin augmentation with MaiLi E. The results showed:

• 64.2% improvement in jawline contour judged by independent investigators at 6 months
• Improvement rate of Global Aesthetic Improvement Scale (GAIS) was 94.3% at 6 months as judged by injection investigators
• 72.6% patient satisfaction reported at 6 months after last injection
• Treatment effects were maintained for 12 months after the last treatment according to the CACRS* score
• MaiLi E patients required fewer touch-ups with less volume compared with the control group
• Reported adverse effects were mostly mild in nature and related to injection site effects

Global Experts Endorse Sinclair’s Innovation in Aesthetic Medicine

Mr. Li Bin, Founder of Lige Group and Vice President of the Chinese Association of Plastics and Aesthetics, delivered the opening address for the Sinclair Global Medical Summit. He explored the continued momentum in medical aesthetics and stressed that innovation, education, and higher aesthetic standards are needed to meet evolving consumer demands. He recognised that Sinclair has always been driven by innovation, and is committed to propelling China’s medical aesthetics industry to new heights. 

The launch event also featured keynote addresses from leading international experts. Dr. Franco Vercesi, Chairman of the Scientific Committee of the Italian Association of Aesthetic Medicine (AMEI) was joined by Dr. Isaac, Founder of Artisan Clinic in Singapore and Director of Health Medicine. These global thought leaders shared their experiences and discussed the ability of MaiLi E to deliver great projection, with less volume of product3. 

Industry Leaders Align with Sinclair’s Patient-Centered Vision

Sinclair also hosted a CEO Leadership Forum, featuring six industry leaders:  Shen Ting, co-founder of Oriental High Definition; Ma Dongsheng, Vice President of the High-Tech and Supply Chain Branch of the China Association of Plastic and Cosmetic Surgery; Sun Qizhi, General Manager of Juan Ya Medical Group; Wang Xiaolu, President of Shenzhen Plastic and Cosmetic Surgery Association; Ma Weiwei, Vice President of Yuansong Group; and Sun Meng, Principal of Hangzhou Enid Medical Cosmetics. 

These experts expressed that their partnership with Sinclair reflects a strong confidence in the brand’s differentiated products and robust reputation, as well as an appreciation for its patient-centered approach to empowering physicians and institutions. Situated at the intersection of technology and aesthetics, Sinclair is redefining the holistic ecosystem of beauty.